The compound MSL, also known as 4-sulfonyl-5-methylthio-2-phenyloxazole, was discovered to activate TFEB and effectively ameliorate adipose inflammation, hyperglycaemia, hepatic steatosis, and obesity in diabetic mice with the ob/ob phenotype [381, 382]. Here, TFEB is linked to Hepatic steatosis.